$TDC

UBS cuts Teradata stock price target on cautious Q3 view

UBS lowered its price target for Teradata (NYSE:TDC) to $32 from $36, citing a cautious view on Q3 results. The firm sees limited upside but potential catalysts in Q4 and fiscal 2027 guidance. Teradata's stock trades at 6x its 2027 free cash flow estimate, with a 27% free cash flow yield. The company recently reported Q2 earnings of $0.69 per share, beating estimates, but management expects a slight decline in recurring revenue for the year's second half.

Original reporting
Published Sep 21, 2026, 2:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 3:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TDC
Bearish
medium confidence
Mentioned
$TDC
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TDCBearishMed
01

Why it matters

The target cut signals a bearish stance, potentially prompting traders to reduce exposure.

02

Market read

Analyst downgrade may trigger short‑term price pressure on TDC and influence sentiment in the analytics sector.

03

What to watch

Hardware tailwinds and improved customer retention may offset Q3 concerns.

Relevance 6/10Novelty 6/10Timing: Friday

Background

UBS revised its outlook for Teradata after meeting with management ahead of the quiet period.

Company-level read

Ticker impact

$TDCBearishMedium confidence
Context

UBS lowered its price target on Teradata to $32, citing a cautious Q3 outlook and limited upside.

Expected impact

Potential short‑term price decline toward $32 target.

Evidence & confidence

Target reduction reflects weaker earnings expectations and limited growth catalysts.

Market effects

Analyst caution may pressure other data‑analytics stocks.

U.S. tech sector sentiment could soften.

Limited; primarily affects U.S. listed analytics firms.

Counterpoint

UBS may be overly pessimistic; recent Q2 beat could support higher valuation.

Key entities

  • Teradata Corp.

    Data analytics firm (NYSE:TDC).

  • UBS

    Investment bank providing the price target revision.

Related articles

$MANHMed

Manhattan Associates, Agilysys, Guidewire Software, Pegasystems, and Teradata Stocks Trade Up, What You Need To Know

Shares of Manhattan Associates, Agilysys, Guidewire Software, Pegasystems, and Teradata rose in afternoon trading after strong quarterly earnings and optimistic corporate commentary about AI-driven growth in enterprise software. Salesforce, CrowdStrike, and Okta reported significant AI-related revenue increases, easing investor concerns about AI disruption. Pegasystems' stock is down 36.2% year-to-date but saw a 6.2% increase on the day.

$TDCMed

Read Analyst Questions From Teradata’s Q2 Earnings Call

Teradata (TDC) reported Q2 revenue of $410M, above the $396.1M estimate, and adjusted EPS of $0.69 versus $0.56. Adjusted operating income was $88M. Management cited strong recurring revenue and margin improvement, plus a shift in on-premise contract revenue recognition that left sales flat YoY. Q3 revenue guidance midpoint was $395.2M, below estimates.

$TDCMed

Teradata Q2 Earnings Call Highlights

Teradata (NYSE:TDC) reported Q2 gross margin up 220 bps to 60.5% and recurring revenue gross margin up 30 bps to 67.8%, attributing outperformance to on-premise revenue recognition timing. Net cash rose to $323 million. The company repurchased about $40 million of stock and paid off $450 million of a term loan. It reaffirmed full-year guidance, raised non-GAAP EPS to $2.65-$2.73, and guided Q3 recurring revenue down 4%-2% and total revenue down 6%-4%.

$TDCMed

Why Is Teradata Stock Falling on Wednesday? - Teradata (NYSE:TDC)

Teradata (TDC) reported Q2 adjusted EPS of 69 cents, above the 56-cent estimate, and sales of $410 million versus $397.1 million expected. For Q3, it guided adjusted EPS of 55 to 59 cents and sales of $391.0 to $399.4 million, both below estimates. FY2026 adjusted EPS was raised to $2.65-$2.73. Barclays cut its price forecast to $27. Shares fell 21.2% to $27.11.